Intravenous albumin in patients with cirrhosis and spontaneous bacterial peritonitis: is it worth the cost?
Brand
R E
RE
D000418:Albumins / Q000008:administration & dosage / Q000191:economics*; D001424:Bacterial Infections / Q000191:economics* / Q000401:mortality / Q000628:therapy; D002439:Cefotaxime / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D017052:Hospital Mortality; D006801:Humans; D007262:Infusions, Intravenous; D008103:Liver Cirrhosis / Q000191:economics* / Q000401:mortality / Q000628:therapy; D010538:Peritonitis / Q000191:economics* / Q000401:mortality / Q000628:therapy; D010952:Plasma Substitutes / Q000008:administration & dosage / Q000191:economics*; D011446:Prospective Studies
D000418:Albumins; D010952:Plasma Substitutes; D002439:Cefotaxime